BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 38724453)

  • 1. Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK).
    Fisher AJ; White M; Goudie N; Kershaw A; Phillipson J; Bardgett M; Lally J; Bevin-Nicholls A; Chadwick T; Bryant A; Russell S; Smith H; Frisby L; Errington R; Carby M; Thompson R; Santhanakrishnan K; Parmar J; Lordan JL; Vale L; Hancock H; Exley C; Gennery AR; Wason JM
    BMJ Open Respir Res; 2024 May; 11(1):. PubMed ID: 38724453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.
    Gautschi F; Vogelmann T; Ortmanns G; Knörr F; Steinack C; Hage R; Nägeli M; Schuurmans MM
    J Clin Apher; 2024 Jun; 39(3):e22128. PubMed ID: 38829041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy options for chronic lung allograft dysfunction-bronchiolitis obliterans syndrome following first-line immunosuppressive strategies: A systematic review.
    Benden C; Haughton M; Leonard S; Huber LC
    J Heart Lung Transplant; 2017 Sep; 36(9):921-933. PubMed ID: 28662986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cessation of extracorporeal photopheresis in chronic lung allograft dysfunction: effects on clinical outcome in adults.
    Robinson CA; Huber L; Murer C; Schuurmans M; Kohler M; Hofbauer G; Benden C
    Swiss Med Wkly; 2017; 147():w14429. PubMed ID: 28488260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.
    Moniodis A; Townsend K; Rabin A; Aloum O; Stempel J; Burkett P; Camp P; Divo M; El-Chemaly S; Mallidi H; Rosas I; Fuhlbrigge A; Koo S; Goldberg HJ
    J Heart Lung Transplant; 2018 Mar; 37(3):340-348. PubMed ID: 28431983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes Following Extracorporeal Photopheresis for Chronic Lung Allograft Dysfunction Following Lung Transplantation: A Single-Center Experience.
    Vazirani J; Routledge D; Snell GI; Watson D; Paraskeva M; Westall GP; Harrison SJ
    Transplant Proc; 2021; 53(1):296-302. PubMed ID: 33039145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation.
    Robinson CA; Inci I; Naegeli M; Murer C; Schuurmans MM; Urosevic-Maiwald M; Schüpbach R; Weder W; Benden C
    Pediatr Transplant; 2018 May; 22(3):e13145. PubMed ID: 29380491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.
    Greer M; Dierich M; De Wall C; Suhling H; Rademacher J; Welte T; Haverich A; Warnecke G; Ivanyi P; Buchholz S; Gottlieb J; Fuehner T
    Am J Transplant; 2013 Apr; 13(4):911-918. PubMed ID: 23406373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lung transplant recipients on long-term extracorporeal photopheresis.
    Isenring B; Robinson C; Buergi U; Schuurmans MM; Kohler M; Huber LC; Benden C
    Clin Transplant; 2017 Oct; 31(10):. PubMed ID: 28653398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Off-Line Extracorporeal Photochemotherapy in Patients with Chronic Lung Allograft Rejection Not Responsive to Conventional Treatment: A 10-Year Single-Centre Analysis.
    Del Fante C; Scudeller L; Oggionni T; Viarengo G; Cemmi F; Morosini M; Cascina A; Meloni F; Perotti C
    Respiration; 2015; 90(2):118-28. PubMed ID: 26112178
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A European Multi-Center Analysis of Extracorporeal Photopheresis as Therapy for Chronic Lung Allograft Dysfunction.
    Benazzo A; Bagnera C; Ius F; Del Fante C; Gottlieb J; Hoetzenecker K; Meloni F; Jaksch P; Greer M
    Transpl Int; 2023; 36():11551. PubMed ID: 38282747
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extracorporeal photophoresis: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(6):1-82. PubMed ID: 23074497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessing treatment outcomes in CLAD: The Hannover-extracorporeal photopheresis model.
    Greer M; Liu B; Magnusson JM; Fuehner T; Schmidt BMW; Deluca D; Falk C; Ius F; Welte T
    J Heart Lung Transplant; 2023 Feb; 42(2):209-217. PubMed ID: 37071121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The efficacy of extracorporeal photopheresis to arrest bronchiolitis obliterans in lung allograft recipients was compared between two automated photopheresis instruments.
    Chionis L; Grossman BJ; Hachem R; Commean P; Derfler MC; Vedantham S; Dodds K; Spitznagel E; Atkinson J; Despotis G
    Transfusion; 2018 Dec; 58(12):2933-2941. PubMed ID: 30312482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ECP as additional immunomodulation in idiopathic hyperammonemia and recurrent hypercapnic respiratory failure early post lung transplantation.
    Steinack C; Robinson CA; Nägeli M; Inci I; Benden C
    J Clin Apher; 2021 Feb; 36(1):186-188. PubMed ID: 32838480
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors Associated With Mortality and Response to Extracorporeal Photopheresis in Lung Allograft Recipients With Bronchiolitis Obliterans Syndrome.
    Karnes HE; Schindler EI; Morrell M; Hachem RR; Berman K; Vedantham S; Atkinson J; Spitznagel E; Despotis GJ
    Transplantation; 2019 May; 103(5):1036-1042. PubMed ID: 30130331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal Photopheresis for Bronchiolitis Obliterans Syndrome After Lung Transplantation.
    Hachem R; Corris P
    Transplantation; 2018 Jul; 102(7):1059-1065. PubMed ID: 29557913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Repair of Acute Respiratory Distress Syndrome by Stromal Cell Administration in COVID-19 (REALIST-COVID-19): A structured summary of a study protocol for a randomised, controlled trial.
    Gorman E; Shankar-Hari M; Hopkins P; Tunnicliffe WS; Perkins GD; Silversides J; McGuigan P; Jackson C; Boyle R; McFerran J; McDowell C; Campbell C; McFarland M; Smythe J; Thompson J; Williams B; Curley G; Laffey JG; Clarke M; O'Kane C; McAuley DF
    Trials; 2020 Jun; 21(1):462. PubMed ID: 32493473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extracorporeal photopheresis to attenuate decline in lung function due to refractory obstructive allograft dysfunction.
    ; Hage CA; Klesney-Tait J; Wille K; Arcasoy S; Yung G; Hertz M; Chan KM; Morrell M; Goldberg H; Vedantham S; Derfler MC; Commean P; Berman K; Spitznagel E; Atkinson J; Despotis G
    Transfus Med; 2021 Aug; 31(4):292-302. PubMed ID: 33955079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An observational study of Donor Ex Vivo Lung Perfusion in UK lung transplantation: DEVELOP-UK.
    Fisher A; Andreasson A; Chrysos A; Lally J; Mamasoula C; Exley C; Wilkinson J; Qian J; Watson G; Lewington O; Chadwick T; McColl E; Pearce M; Mann K; McMeekin N; Vale L; Tsui S; Yonan N; Simon A; Marczin N; Mascaro J; Dark J
    Health Technol Assess; 2016 Nov; 20(85):1-276. PubMed ID: 27897967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.